laruparetigene zovaparvovec

AXP000261.1 · Viral vector gene therapy

Platform
AAV vector
Targets
RPGR
Originator
Applied Genetic Technologies Corporation
Sponsor
Beacon Therapeutics

Names

NameTypeSource
laruparetigene zovaparvovecpreferred namecurator
AGTC-501codecurator
laru-zovasynonymcurator

Virus

Role
In vivo gene transfer
Family
Parvoviridae
Virus
adeno-associated virus
Replication
non replicating
Transgenes
RPGR
Route
subretinal
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (3)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07174726A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis PigmentosaActive not recruitingPhase 22025-09-102029-12-3110X-Linked Retinitis Pigmentosa (XLRP)
NCT04850118A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRPActive not recruitingPhase 2/32024-03-142026-06-3085X-Linked Retinitis Pigmentosa
NCT06275620A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)Enrolling by invitationPhase 22023-11-142025-1124X-Linked Retinitis Pigmentosa
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT06333249A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)Active not recruitingPhase 22021-04-132023-04-1114X-Linked Retinitis Pigmentosaname in title: AGTC-501

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 39643074Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results.American journal of ophthalmology2025name in title: AGTC-501
PMID 40146151Addressing Multiplicity in Retinal Sensitivity Analysis: An Alternative Approach to Assessing Gene Therapy Efficacy in Inherited Retinal Diseases.Translational vision science & technology2025name in abstract: AGTC-501
PMID 40547876Systematic Identification of Candidate Genes for Inherited Retinal Disease Gene Therapy Integrating Worldwide IRD Cohort and Single-Cell Analysis.Journal of ophthalmology2025cited by trial NCT04850118

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 39941570Pre-Clinical and Clinical Advances in Gene Therapy of X-Linked Retinitis Pigmentosa: Hope on the Horizon.Journal of clinical medicine2025name in abstract: AGTC-501
PMID 31910043Toxicity and Efficacy Evaluation of an Adeno-Associated Virus Vector Expressing Codon-Optimized RPGR Delivered by Subretinal Injection in a Canine Model of X-linked Retinitis Pigmentosa.Human gene therapy2020name in abstract: AGTC-501
PMID 32414297Dose Range Finding Studies with Two RPGR Transgenes in a Canine Model of X-Linked Retinitis Pigmentosa Treated with Subretinal Gene Therapy.Human gene therapy2020name in abstract: AGTC-501
PMID 30280954Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 Mice.Human gene therapy. Clinical development2018name in abstract: AGTC-501

Notes

Subretinal AAV gene therapy delivering RPGR for X-linked retinitis pigmentosa, in the phase 2/3 VISTA trial NCT04850118. The capsid is a tyrosine-mutant AAV2 in the sponsor's own naming (AAV2tYF), but no source read here states it, so `strain` is empty. AGTC became Beacon Therapeutics.

How to cite

laruparetigene zovaparvovec (AXP000261.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000261.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.